
    
      In addition to the pharmacokinetic endpoints, the study will assess the safety and
      tolerability of 100 mg once daily (qd) doses of SEN0014196 over 14 days in subjects with HD
      and explore potential biomarkers for use in subsequent Phase 2/3 studies.
    
  